Zhejiang Pharmaceutical Co., Ltd. is a large-scale joint-stock integrated pharmaceutical company established in May 1997. Approved by the China Securities Regulatory Commission in August 1999, the company publicly issued 58 million shares of RMB A shares to the public. In October of the same year, the company's shares were listed on the Shanghai Stock Exchange. By the end of 2018, the registered capital was 960 million yuan and the total assets were 10 billion yuan.
Zhejiang Pharmaceutical now owns Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Branch, Zhejiang Laiyi Biotechnology Co., Ltd., Zhejiang Laiyi Pharmaceutical Co., Ltd., Zhejiang Innovation Biological Co., Ltd., Zhejiang Changhai Pharmaceutical Co., Ltd., Shanghai Weiai Le Health Management Co., Ltd., Zhejiang Xinma Bio-Pharmaceutical Co., Ltd. and other nine major branch companies (subsidiaries) and pharmaceutical industry research institutes, Shanghai Laiyi Biopharmaceutical Research and Development Center, two research and development units, more than 6,800 employees, including various types More than 2,500 professional and technical personnel, accounting for more than 37% of the total number of employees.
At present, Zhejiang Medicine has formed a specialized, large-scale production of fat-soluble vitamins, vitamins, quinolone antibiotics, anti-drug resistant antibiotics and other products. The company's leading products synthetic vitamin E, natural vitamin E, β-carotene, canthaxanthin, vancomycin hydrochloride and teicoplanin and other products in the forefront of international production, the company's preparation products levofloxacin injection (trade name "Lelixin letter "), vancomycin hydrochloride for injection (to be credible), teicoplanin for injection (Galican) has an important position in the domestic market.
Through the serious implementation of the development strategy of “innovation and entrepreneurship, competitive development, science and technology, and talents”, Zhejiang Medicine firmly grasps the main line of product development, highlights structural adjustment, integrates various resources, and strengthens original technological innovation and superior products. Technological innovation, do a good job in DMF file registration and FDA certification for superior varieties, vigorously promote clean production, circular economy, take globalization as a foothold, build a sound market network, establish a good brand image, and create an advanced corporate culture. It has enhanced the core competitiveness of the company. At present, Zhejiang Medicine has developed into a pharmaceutical enterprise with advanced technology, large scale, strong strength and influence on the global market.